Christine Boers-Doets, PhD

Side Effects Expert in Cancer Medication


Founder of CancerMed | NEBK and developer of the TARGET® methodology. Helping patients complete their cancer treatment as planned, by getting a grip on side effects.

About Christine


Side Effects Expert in Cancer Medication

Christine Boers-Doets, PhD, is a side effects expert in cancer medication with more than 40 years of experience in healthcare. She is the founder of CancerMed | NEBK, the Dutch expertise center for side effects of cancer medication, internationally known as CancerMed Side Effects Institute.
Her expertise covers the side effects of all systemic cancer therapies, with particular attention to targeted therapy and immunotherapy. Her deepest specialism is mucocutaneous reactions: side effects of the skin and the mucous membranes.
Christine started out wanting a structured, accredited curriculum for side-effect care. It did not exist, so she built it. That way, healthcare professionals no longer have to piece things together themselves, because the patient in front of them today does not have that time.
Born and raised in Germany, Christine works in Dutch, German and English. Her mission: side effects out of the world, starting in the Netherlands.


The TARGET® methodology

Christine developed the TARGET® methodology: a systematic, structured way to gather all information about a side effect, organize and analyze it, draw a conclusion, and agree on a treatment plan together with the patient. TARGET® stands for six steps:
1. Terminology – naming the side effect correctly
2. Assessment – mapping symptoms and signs
3. Reporting – extent, onset, and what makes it better or worse
4. Grading – determining severity
5. Evaluation – checking the effect, preferably within 48 hours
6. Therapy – the best-fitting treatment for this side effect in this situation
The goal is treatment continuity: completing cancer treatment as planned.


Research

In 2019 Christine obtained her PhD at Leiden University with the thesis Towards a patient-driven approach to adverse events of targeted agents in oncology. The research was carried out at the Department of Medical Oncology of Leiden University Medical Center and at Waterland Hospital in Purmerend.
She began this research in 2008. Her first MASCC meeting, in Athens in 2011, showed her how much knowledge about side effects had already been published and how little of it reached daily clinical practice. Closing that gap has driven her work ever since.
Read the thesis → https://hdl.handle.net/1887/77519


Speaking

Christine has been a keynote speaker at DESO (twice) and KOK and a plenary speaker at the MASCC annual meeting. She presented her research at the joint ESMO/ECCO congress and speaks internationally, including in Austria. She gives keynotes in Dutch, German, and English.
Knowledge fades quickly without habit. That is why her keynotes are often followed by an implementation session, in which participants learn to approach side effects with confidence.


Roles

• Founder, CancerMed | NEBK - Nederlands Expertisecentrum voor Bijwerkingen van Kankermedicatie
• Chair, LOOV, the Dutch national network of oncology nurses and nurse specialists
• Active member, MASCC (Multinational Association of Supportive Care in Cancer)


In het Nederlands

Dr. Christine Boers-Doets is expert in bijwerkingen van kankermedicatie in de solide- en hematologische oncologie en oprichter van CancerMed | NEBK - Nederlands Expertisecentrum voor Bijwerkingen van Kankermedicatie. Zij ontwikkelde de TARGET®-methodiek en verzorgt geaccrediteerde nascholing voor zorgprofessionals. Alles over haar aanbod vind je op https://nebk.nl.


Auf Deutsch

Christine Boers-Doets ist Expertin für Nebenwirkungen von Krebsmedikamenten, Gründerin von CancerMed | NEBK und Entwicklerin der TARGET®-Methodik. Sie ist in Deutschland geboren und aufgewachsen und hält ihre Vorträge auch auf Deutsch. Für Vortragsanfragen erreichen Sie sie unter [email protected].

Contact

For speaking invitations, media requests, and collaborations, contact Christine at [email protected] or connect on LinkedIn.

© 2026 Christine Boers-Doets · CancerMed | NEBK - Nederlands Expertisecentrum voor Bijwerkingen van Kankermedicatie · nebk.nl